Advanced Regenerative Therapies
Pioneering Stem Cell Based Solutions for Complex Conditions
Harnessing Innovation for Unmet Medical Needs
Our Advanced Regenerative Therapies leverage cutting-edge progenitor cell and protein technologies to address challenging medical conditions with limited treatment options. Using a proprietary manufacturing process, we produce ischemia-tolerant mesenchymal stem cells (itMSCs) and neural progenitor cells (itNSCs) in a controlled, low-oxygen environment to maximize therapeutic potential. These therapies are currently in clinical development for neurodegenerative diseases such as Alzheimer’s, ischemic stroke, and spinal cord injury, offering new hope to patients worldwide.
Proprietary Manufacturing Platform
Innovative low-oxygen, low-tension technology enhances cell viability and therapeutic effectiveness.
Targeted Neurological Therapies
itMSCs and itNSCs are being developed for conditions like ischemic stroke, Alzheimer’s, and spinal cord injury.
Clinical-Stage Advancements
Ongoing trials demonstrate the potential of regenerative therapies to address previously untreatable conditions.
Combination Therapy Potential
Exploring multi-cell and cell-protein therapies to target complex degenerative processes more effectively.
Ready to drive healthcare innovation and improve lives with us?
Are you a healthcare leader, government agent, or institution focused on transforming patient care?
We collaborate with organizations and forward-thinking leaders to bring innovative, evidence-based programs to the forefront of healthcare. Join us in shaping a healthier future and delivering exceptional care to your community.